What is Intercept Pharmaceuticals' stock symbol?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
Where is Intercept Pharmaceuticals' stock going? Where will Intercept Pharmaceuticals' stock price be in 2017?
18 analysts have issued twelve-month price targets for Intercept Pharmaceuticals' shares. Their forecasts range from $60.00 to $350.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $188.61 in the next twelve months.
When will Intercept Pharmaceuticals announce their earnings?
Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.
What are analysts saying about Intercept Pharmaceuticals stock?
Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
- BMO Capital Markets analysts commented, "We are raising our PT to $221 from $198 as we believe updated launch metrics suggest continued steady uptake of Ocaliva for PBC driven by greater physician awareness and more open access, supporting our above-consensus 2017 sales estimates. We believe the removal of the REGENERATE enrollment overhang could allow ICPT shares to trade up meaningfully on any signs of efficacy in PSC Ph2 as it remains a source of upside to our and Street estimates. We expect Ocaliva sales growth and development milestones to help ICPT shares recover." (2/24/2017)
- Wedbush analysts commented, "We believe several clinical catalysts later this year could provide upside to ICPT's current price. Q4/FY:16 Financials: Q4/FY:16 Ocaliva sales were $13.4MM/$18.2MM. Revenues of $13.8MM/$24.9MM also came in higher than consensus estimates of $8.96MM/$20.16MM. GAAP (loss) of $(4.84)/$16.74) came in lower than consensus estimates of $(3.68)/($15.63) on higher than expected SG&A expenses. We have incorporated Q4/FY:16 financials and updated our model based on 2017 guidance. ICPT ended 2016 with cash balance of $689.4MM. Progress on the Ocaliva launch. ICPT appears to be making significant progress with reimbursement, with the time to filled-prescription now at three weeks." (2/24/2017)
Needham & Company LLC analysts commented, "Intercept reported 4Q16 financial results today. Ocaliva sales were $13.4M, compared to our $9.0M and consensus $7.8M est. Mgmt cited better than expected gross:net. No sales guidance was issued, as expected, although mgmt indicated 1Q17 sales will only be modestly above 4Q16, w/ expectations for gross:net to worsen. As a reminder, drug was launched in Jun 2016 for treatment of PBC. Ocaliva launch is progressing well, but we believe this is already factored in stock. Mgmt recently negotiated changes to Phase 3 REGENERATE NASH trial design, allowing for smaller pt population. We expect a favorable outcome, but note results will still not be available until 1H19." (2/23/2017)
Cantor Fitzgerald analysts commented, "With concerns in Nov. 2016 to achieve REGENERATE interim enrollment by 1H17, Intercept amended protocols and now expects completion by mid-2017." (2/13/2017)
According to Zacks Investment Research, "Intercept received a major boost with the approval of its lead drug, Ocaliva, in combination with ursodeoxycholic acid (UDCA), for the treatment of primary biliary cholangitis (PBC) in both the U.S. and the EU. Successful commercialization of the drug will significantly boost the company’s revenues, going forward. The PBC market holds strong potential. We are also encouraged by Intercept’s efforts to develop the drug in additional indications. Loss estimates have narrowed lately ahead of the company’s Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters. Moreover, the company’s share price outperformed the industry in the last twelve months. However, expenses will continue to rise in the coming quarters as the company prepares for a potential launch of Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline." (1/19/2017)
Who owns Intercept Pharmaceuticals stock?
Intercept Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Orbimed Advisors LLC (4.51%), State Street Corp (3.03%), Marshall Wace LLP (0.41%), White Square Capital LLP (0.26%) and National Planning Corp (0.21%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, David Shapiro, Jonathan Silverstein, Klaus R Dr Veitinger, Lisa Bright, Luciano Adorini, Mark Pruzanski, Nicole Williams, Orbimed Advisors Llc and Rachel Mcminn.
Who sold Intercept Pharmaceuticals stock? Who is selling Intercept Pharmaceuticals stock?
Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Credit Agricole S A, Metropolitan Life Insurance Co. NY, Van ECK Associates Corp, First Republic Investment Management Inc., Federated Investors Inc. PA and Guggenheim Capital LLC. Company insiders that have sold Intercept Pharmaceuticals stock in the last year include Barbara Gayle Duncan, David Shapiro, Lisa Bright, Mark Pruzanski and Rachel Mcminn.
Who bought Intercept Pharmaceuticals stock? Who is buying Intercept Pharmaceuticals stock?
Intercept Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace LLP, White Square Capital LLP, ING Groep NV, FMR LLC, A.R.T. Advisors LLC, Numeric Investors LLC and WFG Advisors LP.
How do I buy Intercept Pharmaceuticals stock?
Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Intercept Pharmaceuticals stock cost?
One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $127.59.